Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer.

Cytokine gene-engineered tumor vaccines are currently an area of intense investigation in both basic research and clinical medicine. Our efforts to utilize tumor vaccines in an immunotherapeutic manner involve canines with spontaneous tumors. We hypothesized that canine tumor cells, transfected with human granulocyte-macrophage colony-stimulating factor (hGM-CSF) cDNA in a plasmid vector, would prove nontoxic following intradermal administration, generate biologically relevant levels of protein, effect local histological changes at the sites of vaccination, and create a systemic antitumor response. Sixteen tumor-bearing dogs were admitted to a study of ex vivo gene therapy. Tumor tissue was surgically removed, enzymatically and mechanically dissociated, irradiated, transfected, and intradermally injected back into the patients. The dogs were vaccinated with primary autologous tumor cells transfected with hGM-CSF or a reporter control gene. hGM-CSF protein was detected (0.07 to 14.15 ng/vaccination site) at 24 hr postinjection and dramatic histological changes were observed, characterized by neutrophil and macrophage infiltration at the sites of injection of hGM-CSF-transfected tumor cells. This was in stark contrast to the lesser neutrophilic and eosinophilic infiltrates found at control vaccination sites. Objective evidence of an antitumor response was observed in three animals. These data, in a large animal translational model of spontaneous tumors, demonstrate in vivo biological activity of hGM-CSF-transfected autologous tumor cell vaccines.

[1]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[2]  S. Rosenberg.  Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[3]  R. Webster,et al.  Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. , 1997, Journal of immunology.

[4]  H. Qin,et al.  Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. , 1996, Human gene therapy.

[5]  D. Mahvi,et al.  Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. , 1996, Human gene therapy.

[6]  D. Fuller,et al.  Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization , 1996 .

[7]  L. Blackwood,et al.  Radiotherapy of oral malignant melanomas in dogs. , 1996, Journal of the American Veterinary Medical Association.

[8]  N. Yang,et al.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Moss,et al.  Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. , 1996, Cancer research.

[10]  M. Albertini,et al.  Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. , 1996, Cancer gene therapy.

[11]  T. Pugh,et al.  In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. , 1996, Cancer gene therapy.

[12]  J. Krauss,et al.  Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes , 1996, Cancer Immunology, Immunotherapy.

[13]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[14]  H. Wakimoto,et al.  Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. , 1996, Cancer research.

[15]  E. Gilboa.  Immunotherapy of cancer with genetically modified tumor vaccines. , 1996, Seminars in oncology.

[16]  G. Widera,et al.  Particle-mediated nucleic acid immunization. , 1996, Journal of biotechnology.

[17]  S. Calvano,et al.  The effect of granulocyte‐macrophage colony‐stimulating factor on myeloid cells and its clinical applications , 1995, Journal of leukocyte biology.

[18]  J. Malter,et al.  Granulocyte-macrophage colony-stimulating factor mRNA stabilization enhances transgenic expression in normal cells and tissues. , 1995, Blood.

[19]  J. Schlom,et al.  Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. , 1995, Cancer gene therapy.

[20]  W. L. Shupert,et al.  Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. , 1995, Cancer research.

[21]  F. Marshall,et al.  Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[22]  R. Welsh,et al.  Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. , 1995, Journal of immunology.

[23]  J. Armitage,et al.  Clinical applications of hematopoietic growth factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Weiner,et al.  Immunization by direct DNA inoculation induces rejection of tumor cell challenge. , 1995, Human gene therapy.

[25]  T. Pugh,et al.  In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Beissert,et al.  Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.

[27]  F. Marshall,et al.  Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. , 1995, Human gene therapy.

[28]  D. Littman,et al.  The function of the CD4 coreceptor in the development of T cells. , 1995, International reviews of immunology.

[29]  D. Pardoll.  Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[30]  E. Gilboa,et al.  Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. , 1995, Cancer investigation.

[31]  E. Gilboa,et al.  Immunotherapy of cancer using cytokine gene-modified tumor vaccines. , 1994, Seminars in cancer biology.

[32]  B. Gansbacher.  Cytokine gene therapy. , 1994, The Mount Sinai journal of medicine, New York.

[33]  M. Cotten,et al.  Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. , 1994, Gene therapy.

[34]  E. Gilboa,et al.  Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. , 1994, Cancer research.

[35]  J. Vilček,et al.  Monocyte Activation Following Systemic Administration of Granulocyte‐Macrophage Colony‐Stimulating Factor , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[36]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[37]  J. Cebon,et al.  Granulocyte-macrophage colony-stimulating factor for cancer treatment. , 1994, Oncology.

[38]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Fuller,et al.  Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. , 1993, DNA and cell biology.

[40]  N. Yang,et al.  Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. , 1993, Journal of immunological methods.

[41]  N. Yang,et al.  In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Wolff,et al.  Particle Bombardment-Mediated Gene Transfer and Expression in Rat Brain Tissues , 1993, Bio/Technology.

[44]  P. Lange,et al.  Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[46]  E. Macewen,et al.  Effect of colony-stimulating factors on number and function of circulating monocytes in normal dogs. , 1992, Molecular biotherapy.

[47]  N. Yang.  Gene transfer into mammalian somatic cells in vivo. , 1992, Critical reviews in biotechnology.

[48]  J. Gasson.  Molecular physiology of granulocyte-macrophage colony-stimulating factor. , 1991, Blood.

[49]  N. Yang,et al.  In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. McCue,et al.  Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Lerner,et al.  Antibody remodeling: a general solution to the design of a metal-coordination site in an antibody binding pocket. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Scadden,et al.  Hematopoietic growth factors. Biology and clinical applications. , 1989, The New England journal of medicine.

[53]  C. Caskey,et al.  Histochemical staining of clonal mammalian cell lines expressingE. coliβ galactosidase indicates heterogeneous expression of the bacterial gene , 1987, Somatic cell and molecular genetics.

[54]  R. Brodey,et al.  Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. , 1979, Journal of the American Veterinary Medical Association.

[55]  D. Bostock.  Prognosis after Surgical Excision of Canine Melanomas , 1979, Veterinary pathology.

[56]  M. Klauber,et al.  Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. , 1968, Journal of the National Cancer Institute.